SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
DENVER, April 30, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq:ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute has awarded a $3.6 million grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT, a member of the Company’s Quelimmune™ product family) as a bridging strategy to left ventricular assist device (LVAD) implantation in patients with chronic heart failure (CHF) who have progressed to acute decompensated heart failure (ADHF). This grant award follows a Breakthrough Device Designation for cardiorenal syndrome granted by the U.S. Food and Drug Administration (FDA’s) Center for Biologics Evaluation and Research (CBER) in September 2023.